| 000 | 01896 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516193928.0 | ||
| 264 | 0 | _c20140820 | |
| 008 | 201408s 0 0 eng d | ||
| 022 | _a1873-2518 | ||
| 024 | 7 |
_a10.1016/j.vaccine.2014.01.022 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aTinoco, Juan Carlos | |
| 245 | 0 | 0 |
_aImmunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial. _h[electronic resource] |
| 260 |
_bVaccine _cMar 2014 |
||
| 300 |
_a1480-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Viral _xblood |
| 650 | 0 | 4 | _aAntibody Formation |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHemagglutination Inhibition Tests |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfluenza A Virus, H1N1 Subtype |
| 650 | 0 | 4 | _aInfluenza A Virus, H3N2 Subtype |
| 650 | 0 | 4 | _aInfluenza B virus |
| 650 | 0 | 4 |
_aInfluenza Vaccines _xclassification |
| 650 | 0 | 4 |
_aInfluenza, Human _xprevention & control |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aVaccines, Inactivated _xtherapeutic use |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aPavia-Ruz, Noris | |
| 700 | 1 | _aCruz-Valdez, Aurelio | |
| 700 | 1 | _aAranza Doniz, Carlos | |
| 700 | 1 | _aChandrasekaran, Vijayalakshmi | |
| 700 | 1 | _aDewé, Walthère | |
| 700 | 1 | _aLiu, Aixue | |
| 700 | 1 | _aInnis, Bruce L | |
| 700 | 1 | _aJain, Varsha K | |
| 773 | 0 |
_tVaccine _gvol. 32 _gno. 13 _gp. 1480-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.vaccine.2014.01.022 _zAvailable from publisher's website |
| 999 |
_c23506774 _d23506774 |
||